Qiming J. Wang

机构：University of Pittsburgh, Fudan University, Zhengzhou University, Henan Academy of Sciences, Fudan University Shanghai Cancer Center, Henan Cancer Hospital · ORCID：0000-0002-9502-4851

发表论文 110 篇 · 总被引 4445 次 · h-index 36

代表论文

• Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials (2025 · Nature Medicine · 被引 47)
• First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial (2025 · Nature Medicine · 被引 20)
• Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer (2024 · Oncogene · 被引 14)
• Protein kinase D2 confers neuroprotection by promoting AKT and CREB activation in ischemic stroke (2023 · Neurobiology of Disease · 被引 8)
• Lysine demethylase 5D promotes CHEK1 inhibitor sensitivity through p38-mediated cyclooxygenase-2 expression in castration-resistant prostate cancer cells (2025 · Journal of Pharmacology and Experimental Therapeutics · 被引 1)
• [A study of the correlation between gray matter atrophy in multiple sclerosis and impairment of cognitive function domains]. (2024 · PubMed · 被引 1)